The upcoming report from Globus Medical (GMED) is expected to reveal quarterly earnings of $0.74 per share, indicating an increase of 2.8% compared to the year-ago period. Analysts forecast revenues of $628.32 million, representing an increase of 3.6% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Given this perspective, it's time to examine the average forecasts of specific Globus Medical metrics that are routinely monitored and predicted by Wall Street analysts. The collective assessment of analysts points to an estimated 'Net Sales by Product Category- Enabling Technologies' of $38.79 million. The estimate indicates a change of +21.3% from the prior-year quarter. Analysts forecast 'Net Sales by Product Category- Musculoskeletal Solutions' to reach $598.85 million. The estimate points to a change of +4.2% from the year-ago quarter. The consensus among analysts is that 'Geographic Revenues- International' will reach $127.52 million. The estimate indicates a year-over-year change of +3.1%. Based on the collective assessment of analysts, 'Geographic Revenues- United States' should arrive at $510.72 million. The estimate points to a change of +5.8% from the year-ago quarter. View all Key Company Metrics for Globus Medical here>>> Over the past month, Globus Medical shares have recorded returns of +4.5% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), GMED will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues Globus Medical, Inc. (GMED):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...